← Eichor
Study identifier: NCT06960707 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Two Versus One Week Breast Radiotherapy (RT)

Condition: Breast Cancer  ·  Sponsor: Weill Medical College of Cornell University

PhasePhase 3
Planned participants400
Who can joinFemale, N/A to no upper limit
Healthy volunteersNo

About this study

This study is comparing two different radiation therapy approaches for early breast cancer to see which one is better for patients. One group will receive radiation over one week (based on the FAST-FORWARD trial), and the other group will receive radiation over two weeks with an extra focused dose (called a "concomitant boost"). The study will look at how the treatments affect side effects, breast appearance, and cancer control in the breast. It also aims to find out if the two-week treatment does a better job at preventing cancer from coming back in the breast over the long term.

This description comes directly from the study's public registry record.

Talk to the study team

Fabiana Gregucci, MD  ·  6469623110  ·  fgr4002@med.cornell.edu

Fereshteh Talebi, MD  ·  6467027830  ·  fet4007@med.cornell.edu

Always discuss trial participation with your own doctor first.

Locations (3)

Brooklyn Methodist HospitalNew York, New York, United StatesRecruiting
New York Presbyterian HospitalNew York, New York, United StatesRecruiting
New York-Presbyterian Weill Cornell Medical CollegeNew York, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06960707